0001104659-24-000325.txt : 20240102 0001104659-24-000325.hdr.sgml : 20240102 20240102160534 ACCESSION NUMBER: 0001104659-24-000325 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231227 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240102 DATE AS OF CHANGE: 20240102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Journey Medical Corp CENTRAL INDEX KEY: 0001867066 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 471879539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41063 FILM NUMBER: 24502390 BUSINESS ADDRESS: STREET 1: 9237 E VIA DE VENTURA BLVD., SUITE 105 CITY: SCOTTSDALE STATE: AZ ZIP: 85258 BUSINESS PHONE: 480-434-6670 MAIL ADDRESS: STREET 1: 9237 E VIA DE VENTURA BLVD., SUITE 105 CITY: SCOTTSDALE STATE: AZ ZIP: 85258 8-K 1 tm2333941d1_8k.htm FORM 8-K
false 0001867066 0001867066 2023-12-27 2023-12-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): December 27, 2023

 

Journey Medical Corporation

(Exact Name of Registrant as Specified in Charter)

 

Delaware  001-41063  47-1879539
(State or Other Jurisdiction
of Incorporation)		  (Commission File Number)  (IRS Employer Identification No.)

 

9237 E Via de Ventura Blvd., Suite 105

Scottsdale, AZ 85258

(Address of Principal Executive Offices)

 

(480) 434-6670

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act.

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock DERM Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01Entry into a Material Definitive Agreement.

 

On December 27, 2023 (the “Closing Date”), Journey Medical Corporation (the “Company”) entered into a Credit Agreement (the “Credit Agreement”), by and among the Company and SWK Funding LLC and the other the financial institutions party thereto from time to time, as lenders.

 

The Credit Agreement provides for a term loan facility (the “Credit Facility”) in the original principal amount of up to $20 million. On the Closing Date, the Company drew $15 million. The remaining $5 million may be drawn upon request by the Company within 12 months after the Closing Date. Loans under the Credit Facility (the “Term Loans”) mature on December 27, 2027 (the “Maturity Date”) unless the Credit Facility is otherwise terminated pursuant to the terms of the Credit Agreement. Beginning in February 2026, the Company is required to repay the outstanding principal of the Term Loans quarterly in an amount equal to 7.5% of the principal amount of funded Term Loans. If the total revenue of the Company, measured on a trailing twelve-month basis, is greater than $70 million as of December 31, 2025, principal repayment is not required until February 2027, at which point the Company is required to repay the outstanding principal of the Term Loans quarterly in an amount equal to 15% of the principal amount of funded Term Loans.

 

The Term Loans bear interest at a rate per annum equal to the three-month term SOFR (subject to a SOFR floor of 5%) plus 7.75% (the “Loan Rate”). Upon an event of default under the Credit Agreement, the outstanding principal amounts of the Term Loans will accrue interest at a rate per annum equal to the Loan Rate plus three percent (3%), but in no event in excess of the maximum rate of interest allowed under applicable law. All accrued but unpaid interest on the outstanding Term Loans is payable quarterly until the Maturity Date when the then-outstanding principal balance of the Term Loans and all accrued but unpaid interest thereon becomes due and payable.

 

At the Company’s option, the Company may at any time prepay the outstanding principal balance of the Term Loans in whole or in part. Prepayment of the Term Loans is subject to payment of a prepayment premium equal to (i) 2% of the Term Loans prepaid plus the amount of interest that would have been due through the first anniversary of the Closing Date if the Term Loans are prepaid prior to the first anniversary of the Closing Date, (ii) 1% of the Term Loans prepaid if the Term Loans are prepaid on or after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date, or (iii) 0% if prepaid thereafter. Upon repayment in full of the Term Loans, the Company will pay an exit fee equal to 5% of the original principal amount of the Term Loans.

 

On the Closing Date, the Company paid an origination fee equal to $200,000.

 

The obligations under the Credit Facility are secured by all or substantially all of the Company’s assets and the assets of the Company’s subsidiaries.

 

The Credit Agreement contains customary representations and warranties and includes affirmative and negative covenants applicable to the borrowers thereto and their respective subsidiaries. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental compliance, deliver certain financial reports and maintain insurance coverage. The Company is also required to maintain compliance at all times with a minimum liquidity covenant and minimum total revenue covenant at the levels and subject to cure rights as more fully set forth in the Credit Agreement. The negative covenants include, among others, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions.

 

The Credit Agreement also includes customary events of default, including, among other things, non-payment defaults, covenant defaults, inaccuracy of representations and warranties, defaults under any of the loan documents, certain cross-defaults to other indebtedness, certain bankruptcy and insolvency events, invalidity of guarantees or grant of security interest, certain ERISA-related transactions and events, certain orders of forfeiture, change of control, certain undischarged attachments, sequestrations, or similar proceedings, and certain undischarged or non-stayed judgments, in certain cases subject to certain thresholds and grace periods. The occurrence of an event of default could result in the acceleration of the obligations under the Credit Agreement of the Company or other borrowers.

 

The foregoing description of the Credit Agreement is qualified in its entirety by reference to the full text of the Credit Agreement to be filed with a subsequent periodic report of the Company.

 

 

 

 

Item 2.03.Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The disclosures set forth in Item 1.01 of this Current Report on Form 8-K are incorporated by reference herein.

 

Item 8.01.Other Events.

 

On January 2, 2024, the Company issued a press release announcing the entry into the Credit Agreement. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are furnished herewith:

 

Exhibit
Number

 

 

 Description
99.1   Press release issued by Journey Medical Corporation, dated January 2, 2024.
104   Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Journey Medical Corporation
(Registrant)
   
Date: January 2, 2024    
     
By: /s/ Claude Maraoui
    Claude Maraoui
    Chief Executive Officer, President and Director

 

 

 EX-99.1 2 tm2333941d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

 

Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29

 

Scottsdale, AZ – January 2, 2024 – Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company has entered into a credit facility with an affiliate of SWK Holdings Corporation (“SWK”), a specialized finance company with a focus on the global healthcare sector, providing for borrowings of up to $20 million (“Credit Facility”).

 

“This financing strengthens Journey Medical’s balance sheet and provides us with additional operational flexibility. The funding will support general corporate purposes, as well as anticipated expenses for DFD-29, including an upcoming New Drug Application submission and preparation for its potential commercial launch, pending FDA approval,” said Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical.

 

The Credit Facility provides for an initial term loan of $15 million that the Company intends to use to fund general corporate operations and commercial and DFD-29 product development initiatives. The Credit Facility is expected to mature four years from funding and has an initial interest-only period for the first two years, which may be extended to three years based on the achievement of a specified revenue threshold. The Company also has the option to draw an additional tranche of $5 million under the Credit Facility, subject to the achievement of specified operational and financial metrics, in the twelve months following the date of the credit facility.

 

About Journey Medical Corporation

 

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The company currently markets eight branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

 

 

 

 

Forward-Looking Statements

 

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “the Company”, “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words “anticipate,” “believe,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “intend,” “potential” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third- party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful development and regulatory approval of the DFD-29 product candidate and any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2022, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

 

Company Contact:

Jaclyn Jaffe

(781) 652-4500

ir@jmcderm.com

 

Media Relations Contact:

Tony Plohoros

6 Degrees

(908) 591-2839

tplohoros@6degreespr.com

 

 

 

 

 

 

 

 

 EX-101.SCH 3 derm-20231227.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 derm-20231227_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 derm-20231227_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image_002.jpg GRAPHIC begin 644 image_002.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Dec. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 27, 2023
Entity File Number 001-41063
Entity Registrant Name Journey Medical Corporation
Entity Central Index Key 0001867066
Entity Tax Identification Number 47-1879539
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9237 E Via de Ventura Blvd.
Entity Address, Address Line Two Suite 105
Entity Address, City or Town Scottsdale
Entity Address, State or Province AZ
Entity Address, Postal Zip Code 85258
City Area Code 480
Local Phone Number 434-6670
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol DERM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 tm2333941d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001867066 2023-12-27 2023-12-27 iso4217:USD shares iso4217:USD shares false 0001867066 8-K 2023-12-27 Journey Medical Corporation DE 001-41063 47-1879539 9237 E Via de Ventura Blvd. Suite 105 Scottsdale AZ 85258 480 434-6670 false false false false Common Stock DERM NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://journeymedicalcorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports derm-20231227.xsd derm-20231227_lab.xml derm-20231227_pre.xml tm2333941d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333941d1_8k.htm": { "nsprefix": "DERM", "nsuri": "http://journeymedicalcorp.com/20231227", "dts": { "schema": { "local": [ "derm-20231227.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "derm-20231227_lab.xml" ] }, "presentationLink": { "local": [ "derm-20231227_pre.xml" ] }, "inline": { "local": [ "tm2333941d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://journeymedicalcorp.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333941d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333941d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://journeymedicalcorp.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-000325-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-000325-xbrl.zip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end